Organoheterocyclic compounds
Medchemexpress LLC ICA 110381 | 325457-99-6 | 99.8% | 267.11 | 50 MG
ICA 110381 is an orally active Kv7.2/Kv7.3 (KCNQ2/3) potassium channel activator with anticonvulsive properties. It acts as a KCNQ2/Q3 activator and a KCNQ1 antagonist.
- Induces rubidium efflux in an agonist-induced rubidium efflux assay using CHO cells expressing KCNQ2 or KCNQ3 (EC50 = 0.38 μM).
- Inhibits rubidium efflux from CHO cells expressing KCNQ1 (EC50 = 15 μM).
- Increases M-currents (IM) in CA1 pyramidal cells, damping neuronal excitability.
- Elevates the threshold for induction of afterdischarges and reduced seizure severity and duration in fully amygdala-kindled rats.
Medchemexpress LLC Senicapoc | 5 MG
Senicapoc (ICA-17043) is a potent and selective Gardos channel (Ca2+-activated K+ channel; KCa3.1) blocker. It has an IC50 of 11 nM for this blockade and also inhibits Ca2+-induced rubidium flux from human RBCs with an IC50 value of 11 nM. Furthermore, it inhibits RBC dehydration with an IC50 of 30 nM.
- Potent and selective Gardos channel (Ca2+-activated K+ channel; KCa3.1) blocker
- Blocks Ca2+-induced rubidium flux from human RBCs
- Inhibits RBC dehydration
Medchemexpress LLC Ica 110381 | 325457-99-6 | 99.8% | 267.11 | 25 MG
ICA 110381 is an orally active Kv7.2/Kv7.3 (KCNQ2/3) potassium channel activator with anticonvulsive properties. It is a KCNQ2/Q3 activator (EC50=0.38 μM) and a KCNQ1 antagonist (IC50=15 μM). It induces rubidium efflux in CHO cells expressing KCNQ2 or KCNQ3, and inhibits rubidium efflux from CHO cells expressing KCNQ1.
- Increases M-currents (IM) in CA1 pyramidal cells
- Damps neuronal excitability
- Elevates the threshold for induction of afterdischarges in animal studies
- Reduces seizure severity and duration in animal studies
Medchemexpress LLC Benzeneacetamide, 4-fluoro-.alpha.-(4-fluorophenyl)-.alpha.-phenyl- | 289656-45-7 | 99.9% | C20H15F2NO | 1 ML
Senicapoc (ICA-17043) is a potent and selective Gardos channel (Ca2+-activated K+ channel; KCa3.1) blocker with an IC50 of 11 nM. It blocks Ca2+-induced rubidium flux from human red blood cells with an IC50 value of 11 nM and inhibits red blood cell dehydration with an IC50 of 30 nM. This product is intended for research use only.
- Potent and selective Gardos channel blocker
- Blocks calcium-induced rubidium flux from human red blood cells
- Inhibits red blood cell dehydration
- Molecular formula: C20H15F2NO
- CAS number: 289656-45-7
- Purity: 99.9%
Selleck Chemical LLC Senicapoc-E0501-25MG
Senicapoc is a Gardos channel(Ca2 -activated K channel KCa3 1) blocker with an IC50 of 11 nM and produces dose-dependent increases in hemoglobin and decreases in markers of hemolysis Senicapoc blocks Ca2 -induced rubidium flux from human RBCs with an IC50 value of 11 nM and inhibits RBC dehydration with IC50 of 30 nM
Medchemexpress LLC Senicapoc | 289656-45-7 | 99.9% | C20H15F2NO | 50 MG
Senicapoc (ICA-17043) is a potent and selective Gardos channel (Ca2+-activated K+ channel; KCa3.1) blocker. It blocks Ca2+-induced rubidium flux from human RBCs and inhibits RBC dehydration. It has been shown to decrease Gardos channel activity and increase red cell K+ content in vivo. It also reduces airway hyperresponsiveness and vascular remodelling in certain models.
- Potent and selective Gardos channel (Ca2+-activated K+ channel; KCa3.1) blocker
- Blocks Ca2+-induced rubidium flux from human red blood cells
- Inhibits red blood cell dehydration
- Decreases Gardos channel activity and increases red cell K+ content
- Reduces airway hyperresponsiveness and vascular remodelling
Selleck Chemical LLC Senicapoc-E0501-5MG
Senicapoc is a Gardos channel(Ca2 -activated K channel KCa3 1) blocker with an IC50 of 11 nM and produces dose-dependent increases in hemoglobin and decreases in markers of hemolysis Senicapoc blocks Ca2 -induced rubidium flux from human RBCs with an IC50 value of 11 nM and inhibits RBC dehydration with IC50 of 30 nM
Medchemexpress LLC ICA 110381 | 325457-99-6 | 99.8% | 267.11 | 100 MG
ICA 110381 is an orally active Kv7.2/Kv7.3 (KCNQ2/3) potassium channel activator with anticonvulsive properties. It acts as a KCNQ2/Q3 activator with an EC50 of 0.38 μM and also as a KCNQ1 antagonist with an IC50 of 15 μM.
- Can be administered orally.
- Targets specific potassium channels.
- Helps in preventing or reducing the severity of seizures.
- Induces rubidium efflux in CHO cells expressing KCNQ2 or KCNQ3 (EC50 = 0.38 μM).
- Inhibits rubidium efflux from CHO cells expressing KCNQ1 (EC50 = 15 μM).
- Damps neuronal excitability in CA1 pyramidal cells by increasing M-currents (IM), reducing input resistance, and shifting the resting membrane potential hyperpolarizing direction.
- Elevates threshold for afterdischarges, reducing seizure severity and duration in amygdala-kindled rats.
Medchemexpress LLC Senicapoc | 289656-45-7 | 99.9% | C20H15F2NO | 25 MG
Senicapoc is a potent and selective blocker of the Gardos channel, also known as the Ca2+-activated K+ channel or KCa3.1, with an IC50 of 11 nM. It functions by inhibiting red blood cell dehydration and preventing the increase in cellular hemoglobin concentration, thus having significant implications for various conditions.
- Blocks Ca2+-induced rubidium flux from human red blood cells.
- Inhibits red blood cell dehydration with an IC50 of 30 nM.
- Prevents sickled red blood cell dehydration, a key issue in sickle cell disease.
- Reduces airway hyperresponsiveness and eosinophil numbers in asthma models.
- Demonstrated potential applications in acute respiratory distress syndrome, COVID, dehydrated hereditary stomatocytosis, mild cognitive impairment, Alzheimer's disease, and pulmonary fibrosis.